Cassava Sciences, Inc.
SAVA•NASDAQ•Healthcare•Biotechnology

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORichard Barry
Founded1998
Employees30
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.cassavasciences.com
Phone512 501 2444
Address
6801 N. Capital of Texas Highway, Suite 300 Austin, Texas 78731 United States

Corporate Identifiers

CIK0001069530
CUSIP14817C107
ISINUS14817C1071
EIN91-1911336
SIC2834

Leadership Team & Key Executives

Richard Jon Barry
Chief Executive Officer, President and Director
Eric J. Schoen
Chief Financial Officer
R. Christopher Cook J.D.
Chief Operating and Legal Officer
Dr. George Thornton Ph.D.
Senior Vice President of Technology
Michael Zamloot
Senior Vice President of Technical Operations
Freda Nassif
Chief Business Officer and Chief Commercial Officer
Jaren Landen
Chief Clinical Development Officer
Dr. Angélique Bordey Ph.D.
Senior Vice President of Neuroscience
Jack Moore Ph.D.
Senior Vice President of Clinical Development
Dr. Joseph Hulihan M.D.
Chief Medical Officer